Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
NEW YORK, Feb. 05, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased MannKind Corp. (Nasdaq:MNKD) securities between August 10, 2015 and January 5, 2016.
Click here to learn about the case: http://docs.wongesq.com/MNKD-Info-Request-Form-1078. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/MNKD-Info-Request-Form-1078.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
